Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 2581 results for methods

  1. Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]

    Discontinued Reference number: GID-TA10863

    Technology appraisal guidance
    Discontinued

  2. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920

    In development Reference number: GID-TA11482 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

    Discontinued Reference number: GID-HST10033

    Highly specialised technologies guidance
    Discontinued

  5. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]

    In development Reference number: GID-TA11627 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development Reference number: GID-TA11697 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Diabetes - buccal insulin [ID311]

    Discontinued Reference number: GID-TAG244

    Technology appraisal guidance
    Discontinued

  8. Bimekizumab for treating ankylosing spondylitis ID4011

    Discontinued Reference number: GID-TA11171

    Technology appraisal guidance
    Discontinued

  9. Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

    Discontinued Reference number: GID-TA10179

    Technology appraisal guidance
    Discontinued

  10. Bevacizumab for untreated malignant pleural mesothelioma [ID1183]

    Discontinued Reference number: GID-TA10197

    Technology appraisal guidance
    Discontinued

  11. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149

    Technology appraisal guidance
    Discontinued

  12. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued Reference number: GID-TA10345

    Technology appraisal guidance
    Discontinued

  13. Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

    Discontinued Reference number: GID-TA10546

    Technology appraisal guidance
    Discontinued

  14. Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

    Discontinued Reference number: GID-TA10687

    Technology appraisal guidance
    Discontinued

  15. Pelareorep for untreated pancreatic cancer [ID1074]

    Discontinued Reference number: GID-TA10689

    Technology appraisal guidance
    Discontinued